<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>The Miller Lab</title>
    <link>/authors/admin/</link>
      <atom:link href="/authors/admin/index.xml" rel="self" type="application/rss+xml" />
    <description>The Miller Lab</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Sat, 07 Dec 2019 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/MLab_logo_5.png</url>
      <title>The Miller Lab</title>
      <link>/authors/admin/</link>
    </image>
    
    <item>
      <title>Website Development With R</title>
      <link>/post/website-development-using-r/</link>
      <pubDate>Sat, 07 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/post/website-development-using-r/</guid>
      <description>

&lt;h2 id=&#34;overview&#34;&gt;Overview&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;This working document is a rough user guide on how to create a website using R via a package called &lt;code&gt;blogdown&lt;/code&gt;. It will also walk you through opening in account on Netlify, which will host your website.&lt;/li&gt;
&lt;li&gt;There are numerous resources for webpage development, including an amazing bookdown called &amp;ldquo;blogdown: Creating Websites with R Markdown&amp;rdquo; (&lt;a href=&#34;https://bookdown.org/yihui/blogdown/&#34; target=&#34;_blank&#34;&gt;https://bookdown.org/yihui/blogdown/&lt;/a&gt;). We&amp;rsquo;ve created this resource as we have tried to provide details and pearls that we struggled with and we belive these may be helpful to others.&lt;/li&gt;
&lt;li&gt;This is a ongoing, &amp;lsquo;living&amp;rsquo; document that is constantly being edited and expanded. Please provide comments to allow us to optimize this document for all R users.&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&#34;please-see-the-attached-pdf-for-more-information&#34;&gt;Please see the attached PDF for more information.&lt;/h3&gt;

&lt;p&gt;&lt;img src=&#34;./Website_Development_in_R.pdf&#34; alt=&#34;pdf&#34; /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Cutaneous Oncology Research Fellow</title>
      <link>/post/cutaneous-oncology-research-fellow/</link>
      <pubDate>Fri, 06 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/post/cutaneous-oncology-research-fellow/</guid>
      <description>&lt;p&gt;The Massachusetts General Hospital Cancer Center and the Department of Dermatology are offering a 1-2 year research fellowship in cutaneous oncology. This position will provide a unique experience in cutaneous oncology and will include roles in clinical investigation and translational research.&lt;/p&gt;

&lt;p&gt;Please see the attached PDF for more information.&lt;/p&gt;

&lt;p&gt;&lt;img src=&#34;./CORF-post.pdf&#34; alt=&#34;pdf&#34; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Current Fellows&lt;/strong&gt;&lt;br /&gt;
- &lt;a href=&#34;https://www.themillerlab.io/authors/fellows/&#34; target=&#34;_blank&#34;&gt;Sophia Shalhout, PhD&lt;/a&gt;
&lt;img src=&#34;/img/SZS.png&#34; alt=&#34;png&#34; /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Clinical Investigation in cSCC - Updates from ASCO and ESMO</title>
      <link>/talk/mgh_meei_nmsc_program_research_meeting-11_19_19/</link>
      <pubDate>Tue, 19 Nov 2019 07:00:00 +0000</pubDate>
      <guid>/talk/mgh_meei_nmsc_program_research_meeting-11_19_19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2019 ASCO IO Abstracts Review</title>
      <link>/talk/sanofi_expert_series/</link>
      <pubDate>Mon, 07 Oct 2019 15:00:00 +0000</pubDate>
      <guid>/talk/sanofi_expert_series/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Project Data Sphereâ€™s Mentoring Award in Oncology, Advanced Analytics and Regulatory Science</title>
      <link>/funding/pds-award/</link>
      <pubDate>Sun, 01 Sep 2019 09:30:00 +0000</pubDate>
      <guid>/funding/pds-award/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;The Merkel Cell Carcinoma Patient Registry is a multi-institutional collaborative effort that is collecting data on outcomes and events in MCC patients. MCC is the prototypical rare tumor, and this Registry aims to develop new methodologies that will enable investigators to examine real world data in real time. Deliverables from the Registry include: (i) precise patient risk stratification, (ii) real-world data for drug development programs, (iii) identification of optimal sequence and combinations therapies, (iv) uncovering low-incidence toxicities and (v) revelations about best practices, (vi) and the generation of novel testable hypotheses.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma</title>
      <link>/talk/gw_derm_resident_lecture_mcc-04-18-19/</link>
      <pubDate>Thu, 18 Apr 2019 09:00:00 +0000</pubDate>
      <guid>/talk/gw_derm_resident_lecture_mcc-04-18-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies Of Dermatological Significance</title>
      <link>/talk/harvard_derm_resident_mgods-02-08-19/</link>
      <pubDate>Fri, 08 Feb 2019 07:45:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_mgods-02-08-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/gw_derm_resident_lecture_sezary-01-17-19/</link>
      <pubDate>Thu, 17 Jan 2019 14:30:00 +0000</pubDate>
      <guid>/talk/gw_derm_resident_lecture_sezary-01-17-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies of Dermatological Signficance</title>
      <link>/talk/gw_derm_resident_lecture_mgods-01-17-19/</link>
      <pubDate>Thu, 17 Jan 2019 13:00:00 +0000</pubDate>
      <guid>/talk/gw_derm_resident_lecture_mgods-01-17-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Clinical spectrum of cutaneous melanoma morphology.</title>
      <link>/publication/clinical-spectrum-of-melanoma/</link>
      <pubDate>Tue, 01 Jan 2019 00:00:00 +0000</pubDate>
      <guid>/publication/clinical-spectrum-of-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30165162&#34; target=&#34;_blank&#34;&gt;Clinical spectrum of cutaneous melanoma morphology.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Reducing M&amp;M in M&amp;M - Strategies to improve Morbidity and Mortality in Melanoma and Merkel cell carcinoma</title>
      <link>/talk/bidmc_grand_rounds_12_19-18/</link>
      <pubDate>Wed, 19 Dec 2018 08:30:00 +0000</pubDate>
      <guid>/talk/bidmc_grand_rounds_12_19-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>FDA Action in Cutaneous Oncology</title>
      <link>/talk/columbia_derm_resident_regulatory_medicine-11-09-18/</link>
      <pubDate>Fri, 09 Nov 2018 13:00:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_regulatory_medicine-11-09-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/columbia_derm_resident_lecture_sezary-11-09-18/</link>
      <pubDate>Fri, 09 Nov 2018 09:00:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_sezary-11-09-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Eczema Tvecium</title>
      <link>/publication/eczema-tvecium/</link>
      <pubDate>Thu, 01 Nov 2018 00:00:00 +0000</pubDate>
      <guid>/publication/eczema-tvecium/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30454071&#34; target=&#34;_blank&#34;&gt;Kaposi&amp;rsquo;s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>PDS MCC Tumor Registry</title>
      <link>/talk/fda_registries_task_force-10-22-18/</link>
      <pubDate>Mon, 22 Oct 2018 12:00:00 +0000</pubDate>
      <guid>/talk/fda_registries_task_force-10-22-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>PAMPs, DAMPs and Dermatology</title>
      <link>/talk/columbia_derm_resident_lecture_innate_immunity-08-24-18/</link>
      <pubDate>Fri, 24 Aug 2018 11:00:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_innate_immunity-08-24-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>TCRs, Tsubs and dHSRs - T-cell Immunity for the Dermatologist</title>
      <link>/talk/columbia_derm_resident_lecture_t_cell_biology-08-24-18/</link>
      <pubDate>Fri, 24 Aug 2018 09:00:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_t_cell_biology-08-24-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>ECOG ACRIN Paul Carbone, MD Fellowship Award</title>
      <link>/funding/ecog-acrin/</link>
      <pubDate>Sun, 01 Jul 2018 09:30:00 +0000</pubDate>
      <guid>/funding/ecog-acrin/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;Recent therapeutic advancements in melanoma have significantly improved the prognosis for thousands of patients with this life-threatening disease. Identification of key driver mutations in melanoma - such as BRAF - has led to the discovery of oncogene-directed therapies that have profoundly changed the therapeutic landscape in melanoma. Indeed, the development of small-molecule inhibitors of BRAF (e.g. vemurafenib and dabrafenib) and its downstream partner MEK (e.g trametinib and cobimetinib) established a new therapeutic paradigm in the management of melanoma. Nevertheless, despite these recent advancements, the prognosis for patients with metastatic disease remains poor, as resistance to these approaches emerges in the majority of patients. Thus, additional management options are sorely needed. This proposed research is designed to test the hypothesis that targeting the recently identified RNF125-JAK1-AXL/EGFR axis will overcome resistance to BRAF/MEK-targeted therapy. To test this hypothesis, we will conduct an investigator-initiated, Phase Ib/single-arm phase II expansion study with the novel JAK1 inhibitor INCB039110 (INCB) in patients with metastatic BRAF-mutant melanoma co-administered with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. We will also perform correlative studies using novel single-cell resolving technologies on pre- and post-treatment specimens to characterize the effects of targeting the RNF125-JAK1-AXL/EGFR axis on the tumor and its ecosystem in order to identify molecular and cellular determinants of resistance.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Role of CDK7 in Melanoma</title>
      <link>/publication/cdk7/</link>
      <pubDate>Sun, 01 Jul 2018 00:00:00 +0000</pubDate>
      <guid>/publication/cdk7/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/29408204&#34; target=&#34;_blank&#34;&gt;High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma</title>
      <link>/talk/columbia_derm_resident_lecture_mcc-05-18-18/</link>
      <pubDate>Fri, 18 May 2018 13:00:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_mcc-05-18-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The Biology of Cutaneous Oncology</title>
      <link>/talk/columbia_derm_resident_lecture_cancer_biology-05-18-18/</link>
      <pubDate>Fri, 18 May 2018 09:30:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_cancer_biology-05-18-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>PAMPs DAMPs and Dermatology - Innate Immunity for the Dermatologist</title>
      <link>/talk/harvard_derm_resident_lecture_innate_immunity-05-08-18/</link>
      <pubDate>Tue, 08 May 2018 09:30:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_innate_immunity-05-08-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>American Skin Association Research Grant</title>
      <link>/funding/asa/</link>
      <pubDate>Mon, 01 Jan 2018 09:30:00 +0000</pubDate>
      <guid>/funding/asa/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;Recent therapeutic advancements in melanoma have significantly improved the prognosis for thousands of patients with this life-threatening disease. Identification of key driver mutations in melanoma - such as BRAF - has led to the discovery of oncogene-directed therapies that have profoundly changed the therapeutic landscape in melanoma. Indeed, the development of small-molecule inhibitors of BRAF (e.g. vemurafenib and dabrafenib) and its downstream partner MEK (e.g trametinib and cobimetinib) established a new therapeutic paradigm in the management of melanoma. Nevertheless, despite these recent advancements, the prognosis for patients with metastatic disease remains poor, as resistance to these approaches emerges in the majority of patients. Thus, additional management options are sorely needed. This proposed research is designed to test the hypothesis that targeting the recently identified RNF125-JAK1-AXL/EGFR axis will overcome resistance to BRAF/MEK-targeted therapy. To test this hypothesis, we will conduct an investigator-initiated, Phase Ib/single-arm phase II expansion study with the novel JAK1 inhibitor INCB039110 (INCB) in patients with metastatic BRAF-mutant melanoma co-administered with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. We will also perform correlative studies using novel single-cell resolving technologies on pre- and post-treatment specimens to characterize the effects of targeting the RNF125-JAK1-AXL/EGFR axis on the tumor and its ecosystem in order to identify molecular and cellular determinants of resistance.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies Of Dermatological Significance</title>
      <link>/talk/harvard_derm_resident_mgods-12-19-17/</link>
      <pubDate>Tue, 19 Dec 2017 09:30:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_mgods-12-19-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/harvard_derm_resident_lecture_sezary-11-21-17/</link>
      <pubDate>Tue, 21 Nov 2017 10:30:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_sezary-11-21-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A Complete Response in cSCC with Ipi/Nivo</title>
      <link>/publication/cr-ipi-nivo-scc/</link>
      <pubDate>Fri, 08 Sep 2017 00:00:00 +0000</pubDate>
      <guid>/publication/cr-ipi-nivo-scc/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28932782&#34; target=&#34;_blank&#34;&gt;Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/harvard_derm_resident_lecture_sezary-05-30-17/</link>
      <pubDate>Tue, 30 May 2017 11:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_sezary-05-30-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Somatic Driver Mutations in Melanoma</title>
      <link>/publication/somatic-drivers-melanoma/</link>
      <pubDate>Fri, 19 May 2017 00:00:00 +0000</pubDate>
      <guid>/publication/somatic-drivers-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30593&#34; target=&#34;_blank&#34;&gt;Somatic driver mutations in melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies Of Dermatological Significance</title>
      <link>/talk/harvard_derm_resident_mgods-01-31-17/</link>
      <pubDate>Tue, 31 Jan 2017 10:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_mgods-01-31-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A novel multi-CDK inhibitor in Melanoma</title>
      <link>/publication/multi-cdk-inhibitor-in-melanoma/</link>
      <pubDate>Sat, 02 Jul 2016 00:00:00 +0000</pubDate>
      <guid>/publication/multi-cdk-inhibitor-in-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/26810603&#34; target=&#34;_blank&#34;&gt;A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Molecularly Targeted Therapies and Immunotherapies For Melanoma</title>
      <link>/publication/review-of-molecularly-targeted-therapies-and-immunotherapies-for-melanoma/</link>
      <pubDate>Wed, 01 Jun 2016 00:00:00 +0000</pubDate>
      <guid>/publication/review-of-molecularly-targeted-therapies-and-immunotherapies-for-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/25085663&#34; target=&#34;_blank&#34;&gt;Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>CDKs as Therapeutic Targets in Melanoma</title>
      <link>/publication/cdk-inhibotrs-in-melanoma/</link>
      <pubDate>Tue, 17 May 2016 00:00:00 +0000</pubDate>
      <guid>/publication/cdk-inhibotrs-in-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24405945&#34; target=&#34;_blank&#34;&gt;Cyclin-dependent kinases as therapeutic targets in melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Molecular testing in melanoma</title>
      <link>/publication/molecular-testing-in-melanoma/</link>
      <pubDate>Sun, 01 May 2016 00:00:00 +0000</pubDate>
      <guid>/publication/molecular-testing-in-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24534656&#34; target=&#34;_blank&#34;&gt;Commentary: Molecular Testing in Melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Melanoma</title>
      <link>/talk/columbia_derm_resident_lecture_melanoma-03-27-15/</link>
      <pubDate>Fri, 27 Mar 2015 09:00:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_melanoma-03-27-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Biology of Keratinocytes</title>
      <link>/talk/columbia_derm_resident_lecture_keratinocyte_biology-01-28-15/</link>
      <pubDate>Wed, 28 Jan 2015 15:30:00 +0000</pubDate>
      <guid>/talk/columbia_derm_resident_lecture_keratinocyte_biology-01-28-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Parameters for Establishing Humanized Mouse Models</title>
      <link>/publication/parameters-for-establishing-humanized-mouse-models/</link>
      <pubDate>Thu, 01 Apr 2010 00:00:00 +0000</pubDate>
      <guid>/publication/parameters-for-establishing-humanized-mouse-models/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/20096637&#34; target=&#34;_blank&#34;&gt;Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>TLR Activation Abrogates Mixed Chimerism</title>
      <link>/publication/tlr-agonists-abrogate-mixed-chimerism/</link>
      <pubDate>Mon, 01 Dec 2008 00:00:00 +0000</pubDate>
      <guid>/publication/tlr-agonists-abrogate-mixed-chimerism/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19120285&#34; target=&#34;_blank&#34;&gt;TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Viral infection - a potent barrier to transplantation tolerance</title>
      <link>/publication/viral-infection-a-potent-barier-to-transplantation-tolerance/</link>
      <pubDate>Thu, 26 Jun 2008 00:00:00 +0000</pubDate>
      <guid>/publication/viral-infection-a-potent-barier-to-transplantation-tolerance/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/18815618&#34; target=&#34;_blank&#34;&gt;Viral infection: a potent barrier to transplantation tolerance.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>TLR Agonists Abrogate Immunological Tolerance</title>
      <link>/publication/tlr-agonists-abrogate-immune-tolerance/</link>
      <pubDate>Thu, 01 May 2008 00:00:00 +0000</pubDate>
      <guid>/publication/tlr-agonists-abrogate-immune-tolerance/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19380803&#34; target=&#34;_blank&#34;&gt;TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Role of Innate Immunity in Transplantation Tolerance</title>
      <link>/publication/role-of-innate-immunity-in-transplantation-tolerance/</link>
      <pubDate>Tue, 01 Apr 2008 00:00:00 +0000</pubDate>
      <guid>/publication/role-of-innate-immunity-in-transplantation-tolerance/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19166387&#34; target=&#34;_blank&#34;&gt;Role of Innate Immunity in Transplantation Tolerance.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Different mechanisms control peripheral and central tolerance</title>
      <link>/publication/different-mechanisms-control-peripheral-and-central-tolerance-in-hematopoietic-chimeric-mice/</link>
      <pubDate>Sat, 09 Jun 2007 00:00:00 +0000</pubDate>
      <guid>/publication/different-mechanisms-control-peripheral-and-central-tolerance-in-hematopoietic-chimeric-mice/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/17564635&#34; target=&#34;_blank&#34;&gt;Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>American Diabetes Association Physician Scientist Training Award</title>
      <link>/funding/ada-fellowship/</link>
      <pubDate>Fri, 01 Jul 2005 09:30:00 +0000</pubDate>
      <guid>/funding/ada-fellowship/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;The objective of this research was to investigate the ability of mesenchymal stem cells (MSCs), isolated from human bone marrow and human umbilical cord blood, to be used as cellular therapy for diabetes mellitus&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Jellypin -  a lower eukaryotic serine proteinase inhibitor (serpin)</title>
      <link>/publication/jellypin/</link>
      <pubDate>Tue, 21 Sep 2004 00:00:00 +0000</pubDate>
      <guid>/publication/jellypin/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/15362859&#34; target=&#34;_blank&#34;&gt;Identification and activity of a lower eukaryotic serine proteinase inhibitor (serpin) from Cyanea capillata: analysis of a jellyfish serpin, jellypin.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>The Serpin SQN-5</title>
      <link>/publication/the-serpin-sqn-5-is-a-dual-mechanistic-class-inhibitor-of-serine-and-cysteine-proteinases/</link>
      <pubDate>Tue, 05 Mar 2002 00:00:00 +0000</pubDate>
      <guid>/publication/the-serpin-sqn-5-is-a-dual-mechanistic-class-inhibitor-of-serine-and-cysteine-proteinases/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/11863458&#34; target=&#34;_blank&#34;&gt;The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
